Extranodal Marginal Zone Lymphoma
Extranodal marginal zone lymphoma is a major area of interest for the Association International Extranodal Lymphoma Study Group (IELSG), with studies focused on disease control in extranodal sites and on treatment options for newly diagnosed, relapsed, and refractory cases. The research portfolio includes MALT lymphoma and other extranodal presentations requiring systemic therapy.
- Rituximab-based therapy
- BTK inhibitors
- Relapsed or refractory disease
Clinical activity also extends to first-line treatment strategies and maintenance approaches in extranodal disease.
Splenic and Nodal Marginal Zone Lymphoma
The sponsor supports research in splenic marginal zone lymphoma and nodal marginal zone lymphoma, including patients with untreated symptomatic disease and those with prior systemic therapy. These studies examine treatment approaches aimed at controlling lymphoma burden in CD20-positive B-cell lymphoma.
- Splenic marginal zone lymphoma
- Nodal marginal zone lymphoma
- CD20-positive marginal zone B-cell lymphoma
Research activity includes combinations built around anti-CD20 therapy and targeted agents in patients needing systemic treatment.
Ocular Adnexal Lymphoma
IELSG also focuses on ocular adnexal marginal zone lymphoma, a distinct extranodal subtype with specialised therapeutic needs. The research landscape includes infection-related treatment strategies and localised disease management in newly diagnosed patients.
- Ocular adnexal marginal zone lymphoma
- Chlamydophila psittaci-associated disease
- Antibiotic-based therapy
This area reflects interest in lymphoma subtypes linked to specific infectious associations and organ-specific presentation.
Relapsed and Refractory Marginal Zone Lymphoma
A further therapeutic domain is relapsed and refractory marginal zone lymphoma, where the sponsor examines options for patients after prior systemic treatment. The studies include combinations of monoclonal antibodies and small-molecule targeted therapies in difficult-to-treat disease.
- Relapsed marginal zone lymphoma
- Refractory marginal zone lymphoma
- Targeted combination therapy
These trials address treatment settings where durable disease control remains a central clinical need.
